Concepedia

Peggy Wong

PW

14

Publications

574

Citations

12

H-Index

2000

Active since

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Janssen (United States)

Thomas Jefferson University

Springhouse

United States Military Academy

Peggy Wong is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, pharmacology, and pharmacotherapy.

Top concepts

Publications per year

2000–2024

14

Publications

14

Pharmacokinetics, COX-2 specificity, and tolerability of supratherapeutic doses of rofecoxib in humans

Marleen Depré, Elliot Ehrich, Anne Van Hecken et al. · European Journal of Clinical Pharmacology · 2000 · 93 citations

, , +7

Characterization of Etoricoxib, a Novel, Selective COX‐2 Inhibitor

Aimée Dallob, Christopher J. Hawkey, Howard Greenberg et al. · The Journal of Clinical Pharmacology · 2003 · 91 citations

A new cyclooxygenase-2 inhibitor, rofecoxib (VIOXX), did not alter the antiplatelet effects of low-dose aspirin in healthy volunteers.

Howard Greenberg, Keith Gottesdiener, Martha Huntington et al. · PubMed · 2000 · 69 citations

, , +17

Rofecoxib, a COX-2 inhibitor, does not inhibit human gastric mucosal prostaglandin production

Nicholas J. Wight, Keith Gottesdiener, Nigel Garlick et al. · Gastroenterology · 2001 · 62 citations · Full text

, , +6

Modifying effect of dual antiplatelet therapy on incidence of stent thrombosis according to implanted drug-eluting stent type

Edoardo Camenzind, Eric Boersma, William Wijns et al. · European Heart Journal · 2014 · 49 citations · Full text

Rows per page

1–5 of 14